📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:23
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Rs 2.10 Lakh Profit: Star Source Multi Trade Reports Turnaround in Q1 FY27
Star Source Multi Trade Ltd (formerly Chemo Pharma Laboratories) reported a marginal net profit of Rs 2.10 Lakhs for the quarter ended June 30, 2026, marking a turnaround from a massive loss of Rs 11.81 Cr in the same quarter last year. Revenue for the quarter stood at Rs 7.46 Lakhs, compared to zero revenue in both the preceding quarter (March 2026) and the year-ago quarter (June 2025). The company's total expenditure was drastically reduced to Rs 5.36 Lakhs from Rs 11.83 Cr YoY, primarily due to the absence of large 'Other Expenses' that plagued previous periods. Despite the turnaround, the company remains a micro-cap with a market capitalization of just Rs 12 Cr and negative reserves of Rs 2.02 Cr.
Confidence: HIGH
What changedThe company has transitioned from a period of zero revenue and heavy losses to generating small-scale sales and a marginal net profit.
Why it mattersThis turnaround suggests a stabilization of operations and a drastic reduction in overheads, though the absolute scale of business remains extremely small relative to its historical losses.
Net Profit (Q1 FY27): Rs 2.10 LakhsNet Sales (Q1 FY27): Rs 7.46 LakhsRevenue vs TTM Revenue: 7.46%EPS (Basic): Rs 0.14Negative Reserves: Rs 2.02 Cr
📅 Short termThe stock may react positively to the bottom-line turnaround, but the extremely low revenue base will likely limit any sustained rally.
📈 Long termLimited; the company needs to demonstrate a scalable and consistent business model to overcome its accumulated losses and negative reserves.
⚠ Risk flags
- Extremely low revenue scale
- Negative reserves of Rs 2.02 Cr
- Micro-cap liquidity risks
- History of high volatility in expenses
Key Highlights
Net Profit of Rs 2.10 Lakhs in Q1 FY27 vs a loss of Rs 11.81 Cr in Q1 FY26.
Net Sales reached Rs 7.46 Lakhs in Q1 FY27, up from zero revenue in the previous quarter.
Total Expenditure decreased by 99.5% YoY to Rs 5.36 Lakhs from Rs 118.26 Cr (in thousands).
Earnings Per Share (EPS) turned positive at Rs 0.14 compared to -Rs 78.70 in the year-ago period.
Negative Reserves stood at Rs 2.02 Cr as of June 30, 2026.
👀 What to Watch
Investors should monitor if the company can scale its revenue beyond the current micro-levels and sustain this marginal profitability, given its history of significant losses and negative net worth.
Star Source Multi Trade Reports Q1 FY27 Net Profit of ₹2.10 Lakhs; Turnaround from ₹11.8 Cr YoY Loss
Star Source Multi Trade Ltd (formerly Chemo Pharma Laboratories) reported a marginal net profit of ₹2.10 Lakhs for Q1 FY27, a significant recovery from a loss of ₹11.81 Crore in Q1 FY26. Revenue for the quarter reached ₹7.46 Lakhs, compared to zero revenue in both the previous quarter (Mar 2026) and the year-ago quarter (Jun 2025). The turnaround is primarily driven by a massive reduction in 'Other Expenses,' which fell from ₹1,180.12 Lakhs to just ₹2.46 Lakhs YoY. While the return to profitability is positive, the company's operational scale remains extremely small relative to its ₹12 Crore market capitalization.
Confidence: HIGH
What changedThe company transitioned from zero revenue and heavy losses to marginal revenue and a small profit for the quarter ended June 30, 2026.
Why it mattersRepresents a potential bottoming out of the business after a period of massive losses, though the current revenue of ₹7.46 Lakhs remains negligible for a listed entity.
Revenue (Q1 FY27): ₹7.46 LakhsNet Profit (Q1 FY27): ₹2.10 LakhsRevenue vs TTM Revenue: ~7.5%Equity Share Capital: ₹1.50 CrMarket Cap: ₹12 Cr
📅 Short termThe stock may see some positive sentiment due to the turnaround from a large loss, but low liquidity and small absolute profit limit the impact.
📈 Long termLimited; structural growth requires scaling revenue from lakhs to crores consistently to justify the current valuation.
⚠ Risk flags
- Extremely low operational scale
- Micro-cap volatility
- Historical inconsistency in revenue generation
Key Highlights
Net Profit of ₹2.10 Lakhs in Q1 FY27 vs a loss of ₹1,180.51 Lakhs in Q1 FY26
Revenue from operations rose to ₹7.46 Lakhs from zero in the sequential quarter (Mar 2026)
Total expenditure plummeted to ₹5.36 Lakhs from ₹1,182.58 Lakhs in the year-ago period
Basic EPS improved to ₹0.14 from a negative ₹78.70 in June 2025
Other Expenses reduced by 99.7% YoY to ₹2.46 Lakhs
👀 What to Watch
Watch for consistent revenue generation in subsequent quarters to see if this turnaround is sustainable or a one-off stabilization, as the current revenue scale is only ~0.6% of market cap.
